Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28221695 | 1.00 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL16602 | 1.00 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL25362121 | 1.00 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL723808 | 0.97 | GLRA1 (0.39) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL22518913 | 0.94 | KDM4E (0.34) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL2586658 | 0.94 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL583140 | 0.94 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL6237184 | 0.94 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL6237274 | 0.94 | GLRA1 (0.37) | GLRA1SLC6A9OR51E2KDM4ELMNA | |
| SCHEMBL28013370 | 0.92 | GLRA1 (0.32) | GLRA1SLC6A9OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332107-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC (US) | 2025-10-30 | — | — | US | claimed |
| US-12296049-B2 | Immediate release dosage form | KENVUE BRANDS LLC (US) | 2025-05-13 | — | — | US | claimed |
| EP-4473962-A2 | IMMEDIATE RELEASE DOSAGE FORM | Johnson & Johnson Consumer Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| EP-3781136-B1 | IMMEDIATE RELEASE DOSAGE FORM | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-09-25 | — | — | EP | claimed |
| US-20240180821-A1 | ORALLY DISINTEGRATING FILM COMPOSITION OF KETOROLAC AND A METHOD OF PREPARATION THEREOF | LN LABORATORIES PVT LTD (IN) | 2024-06-06 | — | — | US | claimed |
| US-20230414520-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC | 2023-12-28 | — | — | US | claimed |
| WO-2021201805-A1 | NICLOSAMIDE COMPOSITIONS WITH HIGH SOLUBILITY AND BIOAVAILABILITY | IMUNEKS FARMA ILAC SAN. VE TIC. A.S. (TR) | 2021-10-07 | — | — | WO | claimed |
| EP-3781136-A1 | IMMEDIATE RELEASE DOSAGE FORM | Johnson & Johnson Consumer Inc. (US) | 2021-02-24 | — | — | EP | claimed |
| CN-112203645-A | Immediate release dosage form | 强生消费者公司 | 2021-01-08 | — | — | CN | claimed |
| WO-2020194117-A1 | IMMEDIATE RELEASE DOSAGE FORM | JOHNSON & JOHNSON CONSUMER INC. (US) | 2020-10-01 | — | — | WO | claimed |
| EP-1954298-A1 | ORAL THERAPEUTIC COMPOUND DELIVERY SYSTEM | Imaginot Pty Ltd. (AU) | 2008-08-13 | — | — | EP | claimed |
| US-20070141144-A1 | Oral delivery system | KENVUE BRANDS LLC | 2007-06-21 | — | — | US | claimed |
| WO-2007059591-A1 | ORAL THERAPEUTIC COMPOUND DELIVERY SYSTEM | IMAGINOT PTY LTD (AU) | 2007-05-31 | — | — | WO | claimed |
| EP-1761250-A4 | ORAL DELIVERY SYSTEM | IMAGINOT PTY LTD (AU) | 2007-05-09 | — | — | EP | claimed |
| EP-1761250-A1 | ORAL DELIVERY SYSTEM | Imaginot Pty Ltd. (AU) | 2007-03-14 | — | — | EP | claimed |
| EP-1750677-A1 | ORAL THERAPEUTIC COMPOUND DELIVERY SYSTEM | Imaginot Pty Ltd. (AU) | 2007-02-14 | — | — | EP | claimed |
| US-20050276847-A1 | Oral delivery system | IMAGINOT PTY LTD. (AU) | 2005-12-15 | — | — | US | claimed |
| WO-2005115344-A1 | ORAL DELIVERY SYSTEM | IMAGINOT PTY LTD (AU) | 2005-12-08 | — | — | WO | claimed |
| WO-2005115345-A1 | ORAL THERAPEUTIC COMPOUND DELIVERY SYSTEM | IMAGINOT PTY LTD (AU) | 2005-12-08 | — | — | WO | claimed |
| WO-2005011737-A2 | PHARMACEUTICAL COMBINATIONS AND FORMULATIONS WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180821-A1 | ORALLY DISINTEGRATING FILM COMPOSITION OF KETOROLAC AND A METHOD OF PREPARATION THEREOF | SI, TREH, SORD | GLRA1 2607/4885SLC6A9 2225/4885OR51E2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.